Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

• Status: Recruiting
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see whether study participants remain MRD-negative after they stop treatment with venetoclax.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: Adaptive Biotechnologies
• Treatments: Antibodies; Antibodies, Monoclonal; Venetoclax

Criteria

Screening Phase Inclusion Criteria:

• ≥ 18-years-old

• Diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma confirmed by the enrolling institution

• Receiving treatment with a venetoclax-based regimen as defined below:

• Venetoclax monotherapy

• Venetoclax in combination with anti CD20 monoclonal antibody (Patients must have completed the anti CD20 monoclonal antibody portion of the regimen prior to discontinuing therapy)

• Patients must be receiving commercially supplied venetoclax (and anti CD20 monoclonal antibody)Have 3-5 bone marrow aspirate slides (fresh or banked), 3-5 FFPE slides (fresh or banked), available banked tumor cells or DNA, or fresh blood sample collected from the patient at any time from original diagnosis of CLL/SLL to present to identify the CLL/SLL clone(s) for future MRD assessments by clonoSEQ®.

• The screening ID sample (high disease burden sample) can be sent prior to start of venetoclax-based therapy to identify the clone for tracking.

Study Intervention Phase Inclusion Criteria:

• Patients must have received venetoclax-based therapy for at least 6 months (including dose interruptions)

• Patients must have two MRD-negative assessments (defined by ≥ 10^-5 sensitivity) on the peripheral blood by the clonoSEQ® assay at least 28 days apart. Given that MRD status is a dynamic endpoint which may improve with time, if a patient is screen failure based on MRD status (i.e. MRD positive at the 10-5 sensitivity), they may be rescreened to assess for study eligibility. Patients must have achieved a complete or partial remission with the venetoclax-based regimen. Criteria for remission are per iwCLL 2018 guidelines. For this protocol, bone marrow biopsy/aspirate evaluation is not necessary to determine remission status.

Exclusion Criteria (both study phases):

• Participation in a clinical trial that supplies venetoclax and/or anti CD20 monoclonal antibody

• Unwilling or unable to participate in all required study evaluations and procedures.

• Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).